55 articles for O Fedorov
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
Ludwig-Maximilians-Universit£T M£Nchen
Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis.
University of Athens
Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex.
University of Cambridge
Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
Boehringer Ingelheim Rcv
Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit.
Pfizer
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.
The Institute of Cancer Research
Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain.
University of Oxford
Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF.
University of Oxford
Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.
Glaxosmithkline
Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening.
The Institute of Cancer Research
Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
University of Oxford
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
University of Oxford
Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
University of Oxford
7,8-dichloro-1-oxo-ß-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.
Ludwig-Maximilians University of Munich
3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
University of Oxford
Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
Universite£? De Rennes 1
Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor.
Icahn School Of Medicine At Mount Sinai
Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist.
University of Oxford
Discovery of PFI-6, a small-molecule chemical probe for the YEATS domain of MLLT1 and MLLT3.
University of Oxford
Discovery of High-Affinity Small-Molecule Binders of the Epigenetic Reader YEATS4.
Pfizer
Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain.
University of Oxford
Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold.
University of Campinas (Unicamp)
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
University of Sussex
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
Goethe-University Frankfurt
LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor.
University of Oxford
Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia.
University of Oxford
Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B.
Cancer Research Uk Cancer Therapeutics Unit
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
University of Oxford
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
University of Oxford
Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance.
University of Oxford
SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK).
Johann Wolfgang Goethe University
Structural Insights into Interaction Mechanisms of Alternative Piperazine-urea YEATS Domain Binders in MLLT1.
Goethe-University Frankfurt
Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1 (SPIN1).
Icahn School Of Medicine At Mount Sinai
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
Institute of Cancer Research
A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin Function.
University of Oxford
The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains.
University of Oxford
[1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
University of Oxford
Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
University of Cambridge
Structure-Based Approach toward Identification of Inhibitory Fragments for Eleven-Nineteen-Leukemia Protein (ENL).
Goethe-University Frankfurt
Discovery of a novel allosteric inhibitor scaffold for polyadenosine-diphosphate-ribose polymerase 14 (PARP14) macrodomain 2.
University of Oxford
Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies.
University College London
Benzoisoquinolinediones as Potent and Selective Inhibitors of BRPF2 and TAF1/TAF1L Bromodomains.
Bayer
Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug Design.
Sprint Bioscience
Design of a Chemical Probe for the Bromodomain and Plant Homeodomain Finger-Containing (BRPF) Family of Proteins.
University College London
Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
University of Oxford
Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile
Theravance Biopharma R&D Ip
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
Enanta Pharmaceuticals
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
Merck Sharp & Dohme
Imidazenil: a new partial positive allosteric modulator of gamma-aminobutyric acid (GABA) action at GABAA receptors.
Georgetown University